The CCL2-CCR2 axis contributes to an immunosuppressive TME; thus, antagonistic drugs targeting CCR2 may be beneficial for cancer therapy or decrease undesired immune responses in COVID-19 and autoimmune diseases (i.e., nonalcoholic steatohepatitis) (Table S3). This evidence concerns the gene CCR2 and COVID-19.